Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Philip Kantoff and Mark Pomerantz.
Philip Kantoff
Connection Strength
4.018
Mark Pomerantz
  1. Genetic determinants of prostate cancer risk. BJU Int. 2007 Aug; 100(2):241-3.
    View in: PubMed
    Score: 0.356
  2. Advances in the treatment of prostate cancer. Annu Rev Med. 2007; 58:205-20.
    View in: PubMed
    Score: 0.346
  3. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
    View in: PubMed
    Score: 0.203
  4. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80.
    View in: PubMed
    Score: 0.194
  5. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
    View in: PubMed
    Score: 0.180
  6. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
    View in: PubMed
    Score: 0.178
  7. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2016 Feb 01; 34(4):352-9.
    View in: PubMed
    Score: 0.161
  8. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
    View in: PubMed
    Score: 0.159
  9. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
    View in: PubMed
    Score: 0.156
  10. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
    View in: PubMed
    Score: 0.135
  11. Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. J Clin Oncol. 2013 Feb 20; 31(6_suppl):157.
    View in: PubMed
    Score: 0.132
  12. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 01; 72(10):1093-103.
    View in: PubMed
    Score: 0.122
  13. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50.
    View in: PubMed
    Score: 0.120
  14. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
    View in: PubMed
    Score: 0.117
  15. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28.
    View in: PubMed
    Score: 0.115
  16. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52.
    View in: PubMed
    Score: 0.114
  17. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.113
  18. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51.
    View in: PubMed
    Score: 0.112
  19. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.103
  20. Quantitative gene expression at the 8q24 prostate cancer risk locus. J Clin Oncol. 2008 May 20; 26(15_suppl):5055.
    View in: PubMed
    Score: 0.095
  21. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
    View in: PubMed
    Score: 0.089
  22. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560.
    View in: PubMed
    Score: 0.083
  23. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
    View in: PubMed
    Score: 0.056
  24. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
    View in: PubMed
    Score: 0.049
  25. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
    View in: PubMed
    Score: 0.048
  26. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA Oncol. 2018 Apr 01; 4(4):558-562.
    View in: PubMed
    Score: 0.047
  27. A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate. 2016 10; 76(14):1338-41.
    View in: PubMed
    Score: 0.042
  28. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
    View in: PubMed
    Score: 0.040
  29. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet. 2015 Apr; 134(4):439-50.
    View in: PubMed
    Score: 0.038
  30. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. J Urol. 2015 Jul; 194(1):91-7.
    View in: PubMed
    Score: 0.038
  31. Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. J Clin Oncol. 2013 Feb 20; 31(6_suppl):33.
    View in: PubMed
    Score: 0.033
  32. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.033
  33. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
    View in: PubMed
    Score: 0.032
  34. Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
    View in: PubMed
    Score: 0.029
  35. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8.
    View in: PubMed
    Score: 0.028
  36. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597.
    View in: PubMed
    Score: 0.026
  37. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.025
  38. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7.
    View in: PubMed
    Score: 0.025
  39. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
    View in: PubMed
    Score: 0.024
  40. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.